Search Medical Condition
Please enter condition
Please choose location

Plymouth, Minnesota Clinical Trials

A listing of Plymouth, Minnesota clinical trials actively recruiting patient volunteers.

RESULTS

Found (245) clinical trials

Octagam 5% Versus Comparator Post Marketing Trial

This Post Marketing Study is a prospective, 2-armed, multicenter, non-interventional study. Patients will either be administered the brand of IGIV therapy ordered by their prescribing physician, or for patients issued unspecified or generic prescriptions of IGIV therapy, octagam® 5% or another brand of IGIV therapy will be provided by the ...

Phase N/A

1.64 miles

Learn More »

Three Doses of Lasmiditan (50 mg 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

Subjects will be asked to treat a migraine attack with study drug on an outpatient basis. Subjects will be provided with a dosing card containing a dose for initial treatment and a second dose to be used for rescue or recurrence of migraine. Each subject's study participation will consist of ...

Phase

1.8 miles

Learn More »

A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.

Phase N/A

1.8 miles

Learn More »

Efficacy and Safety Study of RAGWITEK (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

The purpose of this study is to assess the efficacy and safety of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, MK-3641, SCH 039641, RAGWITEK™) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced allergic rhinitis/rhinoconjunctivitis with or without asthma. The primary hypothesis of this study is that administration ...

Phase

1.8 miles

Learn More »

PALISADE Follow-on Study (ARC004)

This is an international, multicenter, open-label, 2-arm follow-on study of the safety, tolerability, and efficacy of AR101 in peanut-allergic individuals who have completed the ARC003 study. This study will explore alternative dosing regimens during extended maintenance with AR101.

Phase

1.8 miles

Learn More »

Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis

Study is conducted in 2 parts: part A and part B. Part A - Patients with moderate-to-severe AD will be randomized to receive dupilumab (dose 1) by auto-injector (AI) device or prefilled syringe. Once part A is completely enrolled, part B will randomize patients with moderate-to-severe AD to receive dupilumab ...

Phase

1.8 miles

Learn More »

Efficacy and Safety of Dupilumab in Patients 12 to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

To demonstrate the efficacy of dupilumab as a monotherapy in patients ≥12 years to <18 years of age with moderate-to-severe atopic dermatitis (AD)

Phase

1.8 miles

Learn More »

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children

The primary objective is to assess the safety and tolerability of AR101 when used in a CODIT™ regimen for approximately 6 months in peanut-allergic children.

Phase

1.8 miles

Learn More »

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

This study will evaluate higher versus standard adalimumab dosing regimens for induction and maintenance therapy in subjects with moderately to severely active Crohn's Disease and evidence of mucosal ulceration.

Phase

2.54 miles

Learn More »

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

RECD3126 is a double-blind, placebo-controlled, parallel-group, multicenter, multiregional, 52-week study to assess the efficacy and safety of rifaximin DR tablets for the induction of clinical remission and endoscopic response at 16 weeks followed by clinical and endoscopic remission after 52 weeks of continuous therapy in subjects with active moderate Crohn's ...

Phase

2.54 miles

Learn More »